Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?

European journal of clinical pharmacology - 1 May 2011

Bellanti Francesco, Kågedal Bertil, Della Pasqua Oscar

Abstract excerpt

PURPOSE: Neuroblastoma is the most common extracranial solid tumour in childhood. It accounts for 15% of all paediatric oncology deaths. In the last few decades, improvement in treatment outcome for high-risk patients has not occurred, with an overall survival rate <30-40%. Many reasons may account for such a low survival rate. The aim of this review is to evaluate whether pharmacogenetic factors can explain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Child
Share to MYCN gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neuroblastoma

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 21287160
DOI: 10.1007/s00228-010-0966-3
PMCID: PMC3112027

Genes

MYCN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?PMID 21287160Read ↗

Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?Semantic proximity Read ↗

Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastomaSemantic proximity Read ↗

Neuroblastoma treatment in the post-genomic eraSemantic proximity Read ↗

MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients.Semantic proximity Read ↗

Too many targets, not enough patients: rethinking neuroblastoma clinical trials.Semantic proximity Read ↗

Investigational drugs in phase II clinical trials for the treatment of neuroblastomaSemantic proximity Read ↗

The role of germline variants in chemotherapy outcome in brain tumors: a systematic review of pharmacogenetic studies.Semantic proximity Read ↗

Association of CYP3A4/5 genotypes and expression with the survival of patients with neuroblastoma.Semantic proximity Read ↗

Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcome.Semantic proximity Read ↗

Genetic parameters of neuroblastomasSemantic proximity Read ↗

Association of PARP1 polymorphisms with response to chemotherapy in patients with high-risk neuroblastoma.Semantic proximity Read ↗

Polymorphisms in genes encoding drug metabolizing enzymes and their influence on the outcome of children with neuroblastoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.